不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
第 100 天 NK 细胞/CD14+HLA-DR(DIM) 比值与淋巴瘤自体外周血造血干细胞移植后生存
英文原题：Day 100 Natural Killer Cell/CD14+HLA-DR(DIM) ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
查看英文原题
Day 100 Natural Killer Cell/CD14+HLA-DR(DIM) ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
第 100 天 NKC/CD14 + HLA-DR DIM 比值是淋巴瘤患者 APBHSCT 后的预后免疫生物标志物。
研究思路结论见上方概要
背景
自体移植物NK 细胞（NKC）/CD14 + HLA-DR DIM比值的输注是接受自体外周血造血干细胞移植（APBHSCT）的淋巴瘤患者生存的预测因素。本研究评估了第100天NKC/CD14 + HLA-DR DIM比值是否仍可作为预后免疫生物标志物。
方法
这是一项回顾性、单机构队列分析，纳入我们先前III期试验中在APBHSCT后第100天进行临床评估的107例患者。我们评估了第100天NKC/CD14 + HLA-DR DIM比值预测总生存期（OS）和无进展生存期（PFS）的预后能力，采用Cox回归模型进行结局分析，并采用Kaplan-Meier法分析生存情况。
结果
整个队列自第100天起的中位随访时间为94.7个月（范围4.83-158.1个月）。第100天NKC/CD14 + HLA-DR DIM比值≥1.67的患者相比第100天NKC/CD14 + HLA-DR DIM比值<1.67的患者，OS和PFS更优：中位OS未达到 vs 49.7个月，5年OS率分别为91%（95% CI，81%-96%）vs 40%（95% CI，27%-55%），p < .0001；中位PFS未达到 vs 23.5个月，5年PFS率分别为66%（95% CI，55%-81%）vs 21%（95% CI，15%-40%），p < .0001。多因素分析中，第100天NKC/CD14 + HLA-DR DIM比值是OS和PFS的独立预测因素。
展开英文摘要原文
METHODS
This was a retrospective, single-institution, cohort analysis including 107 patients in this study that had clinical assessment at Day 100 post-APBHSCT from our prior phase III trial. We evaluated the prognostic ability of the Day 100 NKC/CD14 + HLA-DR DIM ratio to predict overall survival (OS) and progression-free survival (PFS) using Cox regression model for outcome analysis and survival by Kaplan-Meier method.
RESULTS
The median follow-up from day 100 was 94.7 months (range 4.83-158.1 months) for the entire cohort. Patients with a Day 100 NKC/CD14 + HLA-DR DIM ratio ≥1.67 experienced better OS and PFS versus those with a Day 100 NKC/CD14 + HLA-DR DIM ratio <1.67: median OS was not reached versus 49.7 months, the 5-year OS rates were 91% (95% CI, 81%-96%) versus 40% (95% CI, 27%-55%), p < .0001, respectively; and median PFS was not reached versus 23.5 months, the 5-year PFS rates were 66% (95% CI, 55%-81%) versus 21% (95% CI, 15%-40%), p < .0001, respectively. Day 100 NKC/CD14 + HLA-DR DIM ratio was an independent predictor for OS and PFS in the multivariate analysis.
CONCLUSIONS
Day 100 NKC/CD14 + HLA-DR DIM ratio is a prognostic immune-biomarker in lymphoma patients post- APBHSCT.
论文信息
- 作者
- Porrata LF、Ansell SM、Micallef IN、Johnston PB、Villasboas JC、Paludo J、Durani U、Markovic SN
- 第一作者单位
- Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.United States
- 通讯作者单位
- Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.United States
- 期刊
- Clinical transplantation2024 Jan
- 原文标识
- PubMed 38041479 · DOI 10.1111/ctr.15211